focus -WSS

focus

author：knowledge 2025-10-02 22:56:50 - browse：65

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Physician assistants need a new name. Here's what it should be

leisure time

knowledge

WSS

Ascension's ugly legal battle over care for poor patients in Texas

The untold story of TV’s first prescription drug ad

Medicare drug price negotiation hearing pits pharma v Biden admin

State of the Union pitch: Bigger Medicare drug price negotiations

Physician assistants need a new name. Here's what it should be

Fetal cell organoids grown from amniotic fluid, study finds

hotspot

focus

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Families look for replacement for GSK asthma drug Flovent

Supreme Court strikes down use of affirmative action

He's 19 months old and has one of the world’s rarest diseases

Anesthesiologist group: stop taking Ozempic before surgery

Change Healthcare: What is it, why does its cyberattack matter?

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: BridgeBio, Akero, and human embryo models

As demand for Covid shots wanes, Moderna seeks its next success

Medicare Advantage coverage denials need scrutiny, senators say

focus

Boston Scientific acquires urology company Axonics for $3.7 billion

Medicare Advantage overpayments discussion gets experts fired up

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

A preacher's new calling: Diversifying neuroscience research

STAT Virtual Event: JPM Recap, Live!

Life science postdocs should get big pay hike, NIH panel says

focus

leisure time

knowledge

leisure time